Loading...
XSHG
603880
Market cap190mUSD
Apr 11, Last price  
4.87CNY
1D
0.21%
1Q
20.25%
IPO
-25.10%
Name

Jiangsu Nanfang Medical Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
2.32
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.05%
Rev. gr., 5y
4.57%
Revenues
600m
+10.03%
424,621,054510,798,291469,803,419433,022,478444,235,500488,708,743479,823,815491,688,0111,072,399,917527,440,662545,369,151600,095,343
Net income
-147m
35,767,10348,044,64553,380,20051,242,68651,980,39047,601,36739,250,11928,051,59598,067,61300-147,417,266
CFO
16m
-50.41%
76,074,46920,142,29873,518,72690,664,00699,350,00149,236,92652,749,49232,994,069154,122,592031,276,44815,509,531
Dividend
May 21, 20210.115385 CNY/sh
Earnings
Apr 18, 2025

Profile

Jiangsu Nanfang Medical Co., Ltd. engages in the research and development, production, and sale of transdermal products, medical proof fabrics, adhesive tapes, bandages, sports protection products, first-aid kits, and care products in China and internationally. It offers medical adhesive tapes, medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, zinc oxide adhesive plasters, and masks, as well as customized products. The company was founded in 1990 and is based in Changzhou, China.
URL
https://www.nfmedical.com.cn/
IPO date
Aug 07, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
600,095
10.03%
545,369
3.40%
Cost of revenue
620,251
524,065
Unusual Expense (Income)
NOPBT
(20,155)
21,304
NOPBT Margin
3.91%
Operating Taxes
(1,230)
Tax Rate
NOPAT
(18,925)
21,304
Net income
(147,417)
 
Dividends
(21,633)
Dividend yield
1.47%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
452,034
456,276
Long-term debt
836
17,863
Deferred revenue
7,580
8,059
Other long-term liabilities
1
Net debt
295,481
285,752
Cash flow
Cash from operating activities
15,510
31,276
CAPEX
(66,160)
Cash from investing activities
(16,353)
Cash from financing activities
125,534
FCF
120,304
(69,038)
Balance
Cash
118,196
149,045
Long term investments
39,193
39,342
Excess cash
127,384
161,118
Stockholders' equity
330,229
500,735
Invested Capital
806,867
937,177
ROIC
2.41%
ROCE
1.93%
EV
Common stock shares outstanding
289,053
289,042
Price
5.09
-17.90%
6.20
-13.41%
Market cap
1,471,282
-17.90%
1,792,060
-14.42%
EV
1,771,714
2,082,635
EBITDA
36,824
62,916
EV/EBITDA
48.11
33.10
Interest
23,188
20,177
Interest/NOPBT
94.71%